Protective effect of the Japanese traditional medicine juzentaihoto on myelosuppression induced by the anticancer drug TS-1 and identification of a potential biomarker of this effect by Kazuo Ogawa et al.
Ogawa et al. BMC Complementary and Alternative Medicine 2012, 12:118
http://www.biomedcentral.com/1472-6882/12/118RESEARCH ARTICLE Open AccessProtective effect of the Japanese traditional
medicine juzentaihoto on myelosuppression
induced by the anticancer drug TS-1 and
identification of a potential biomarker of this
effect
Kazuo Ogawa1*, Tatsushi Omatsu2, Chinami Matsumoto1, Naoko Tsuchiya1, Masahiro Yamamoto1,
Yuji Naito2 and Toshikazu Yoshikawa2Abstract
Background: TS-1 is an oral anticancer drug containing a 5-fluorouracil derivative (Tegafur) that is widely used in
Japan for the treatment of cancer, especially gastrointestinal tumors. Frequently, however, TS-1 therapy has to be
discontinued because of leukopenia. If it were possible to predict the development of bone marrow suppression
before the white blood cell (WBC) count had actually decreased, treatment could be improved by strict dosage
control and/or the prophylactic administration of hematopoietic drugs. Juzentaihoto (JTT), a traditional Japanese
medicine (Kampo), has been reported to activate hematopoiesis and reduce the side effects associated with
chemotherapy and radiotherapy. Here, we 1) evaluate the efficacy of JTT in alleviating myelosuppression induced
by TS-1 therapy in mice, and 2) explore biomarkers that reflect both induction by TS-1 and alleviation by JTT of
bone marrow suppression using a proteomics approach.
Methods: Ten mg/kg of TS-1 was administered to Balb/c mice with or without 1 g/kg of oral JTT for 3, 5 and
7 days. WBC count and ratio of CD34+ bone marrow cells (BMCs) were estimated by flow cytometry. Plasma
samples were analyzed using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI
TOF-MS). A biomarker candidate from SELDI profiling was identified using a combination of cation exchange spin
column purification, SDS-PAGE, enzymatic digestion and LC-MS/MS.
Results: After administration of TS-1, a significant decrease in WBC count and CD34+ BMC ratio were observed at
days 5 and 3, respectively. JTT treatment improved WBC count on day 7 and CD34+ BMC ratio on days 5 and 7.
SELDI analysis highlighted three protein peaks that had increased on day 3 after treatment with TS-1 but remained
unchanged in mice co-treated with JTT. One of the three peaks, m/z 4223.1, was further investigated and identified
as a specific C-terminal fragment of albumin.
Conclusion: This study indicates that bone marrow suppression by treatment with TS-1 in mice might be
improved by coadministration of JTT. A C-terminal fragment of albumin was identified as a candidate biomarker for
predicting TS-1-induced myelosuppression. However, the sensitivity and specificity of the biomarker candidate must
be validated in future clinical studies.
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TS-1 (Taiho Pharmaceutical Co., Ltd, Tokyo, Japan) is
an oral fluoropyrimidine derivative consisting of Tegafur
(FT) and two modulators, 5-chloro-2,4-dihydroxypyrimi-
dine (gimeracil, CDHP) and potassium oxonate (oteracil
potassium, Oxo), an enhancer of FT bioavailability and a
soothing agent of gastrointestinal toxicity, respectively
[1,2]. TS-1 has been widely used in Japan for the treat-
ment of various tumors due to its high therapeutic effi-
cacy and relative low gastrointestinal toxicity [3].
However, TS-1 does not have a component that is effi-
cient in reducing myelosuppression. Indeed, in clinical
practice TS-1 therapy often has to be discontinued be-
cause of leukopenia. However, the survival and quality of
life of patients may be seriously threatened by the dis-
continuation of TS-1 therapy.
Currently, a number of traditional Japanese (“Kampo”)
medicines are manufactured on a modern industrial
scale under strict scientific quality controls. More than
100 Kampo medicines have been approved as ethical
drugs by the Ministry of Health, Welfare and Labor of
Japan, and are used clinically for the treatment of a wide
variety of diseases. One such Kampo medicine, Juzentai-
hoto (JTT), is known to improve the general systemic
condition of cancer patients by reducing the adverse
effects of chemotherapy, radiation therapy and surgical
treatment [4]. Experimental studies suggest that JTT
increases the number of hematopoietic stem cells [5]
and reduces cis-diamminedichloroplatinum(II) (CDDP)-
induced severe bone marrow toxicity in mice [6]. If JTT
can alleviate the bone marrow suppression induced by
TS-1, more patients could receive the benefits of this
drug for a longer period of time.
A lot of research effort is being devoted to identifying
biomarkers that lead to the early diagnosis of various dis-
eases using proteomics technologies. Early and accurate
diagnosis of a disease is critically important because the
patient can then receive prompt and effective therapy.
Often, an otherwise treatable condition becomes untreat-
able at an advanced stage of the disease. A similar situ-
ation can exist during the development of complications
brought about by chemotherapy and radiation therapy.
Thus, a biomarker that is able to detect the early onset of
a side effect, such as bone marrow suppression before a
detectable decrease in WBC count, would allow the pa-
tient to receive more appropriate treatment (e.g., strict
anticancer dosage control and/or prophylactic adminis-
tration of hematopoietic drugs). Mass spectrometry
(MS)-based protein analysis, such as surface-enhanced
laser desorption/ionization (SELDI) technology, is a
high-throughput proteomic technique that has been used
for the discovery of disease-related biomarkers in bio-
logical fluids such as plasma, serum, tissue and urine.
This technique has been employed to identify a numberof biomarkers associated with cancer [7-10], Alzheimer’s
disease [11] and non-alcoholic fatty liver disease [12].
In this study, we had two main aims: (i) to assess the
efficacy of JTT in alleviating bone marrow suppression
induced by TS-1 therapy in vivo; and (ii) to identify can-
didate biomarkers to predict bone marrow suppression
by TS-1 treatment before the onset of recognizable
leucopenia. To generate a shortlist of candidate peaks,
those that were altered by TS-1 treatment but whose
change was reversed by JTT-co-treatment were identi-
fied. This meant that the peaks might also be used as
predictors of whether JTT is effective in preventing or
retarding TS-1-mediated bone marrow suppression in
the early period of TS-1 treatment.
Methods
Drugs
A bulk powder of TS-1 was kindly provided by Taiho
Pharmaceutical Co., Ltd, (Tokyo, Japan). TS-1 is an oral
fluoropyrimidine derivative consisting of FT and two
modulators, CDHP and Oxo, in a molar ratio of 1:0.4:1
[1,2]. FT is a prodrug of 5-fluorouracil (5-FU), and
CDHP is a reversible competitive inhibitor of an enzyme
involved in the degradation of 5-FU. Therefore, CDHP
increases the residence time of the FT-derivative of 5-FU
in the tumor tissue, enhancing the antitumor effect. Oxo
is mainly distributed in the gastrointestinal tract after
per os administration to patients, leading to relief of
gastrointestinal toxicity induced by 5-FU [13,14].
Juzentaihoto (JTT) was obtained from Tsumura & Co.
(Tokyo, Japan). JTT was prepared as a spray-dried pow-
der of a hot water extract obtained from ten medical
plants in the following ratio: Astragali Radix (3.0 g),
Cinamomi Cortex (3.0 g), Rehmanniae Radix (3.0 g),
Paeoniae Radix (3.0 g), Cnidii Rhizoma (3.0 g), Angelicae
Radix (3.0 g), Ginseng Radix (3.0 g), Hoelen (3.0 g), Gly-
cyrrhizae Radix (1.5 g) and Atractylodis Lanceae Rhi-
zoma (3.0 g). TS-1 was dissolved in a 0.5% (w/v)
hydroxypropylmethylcellulose (HPMC) solution, and
JTT was dissolved in distilled water (DW) immediately
before use.
Mice
Six-week-old female specific pathogen-free (SPF) Balb/c
mice were purchased from Japan SLC, Inc. (Shizuoka,
Japan) and maintained under a constant temperature,
humidity and light-controlled environment with free ac-
cess to food and water. The mice were examined after
one-week standardizing diet prior to dosing.
Treatment of animals and evaluation of
myelosuppression
Mice were treated orally as follows: 10 mL/kg of 0.5%
HPMC and 10 mL/kg of DW were administered to
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10 mL/kg of JTT were administered to the JTT group;
10 mg/10 mL/kg of TS-1 and 10 mL/kg of DW were
administered to the TS-1 group; and 10 mg/10 mL/kg
of TS-1 and 1 g/10 mL/kg of JTT were administered
to the TS-1 + JTT group for 3, 5 and 7 days. Mice
were anesthetized with diethyl ether and heparinized
blood samples were collected from the inferior vena
cava of the mice on days 3, 5 and 7 (Figure 1). For
blood cell analysis, EDTA was added to the blood
sample (150 μL at a final concentration of 1 mg/mL)
and shaken well. The number of white blood cells
(WBCs) was immediately counted using a Sysmex XT-
2000i V (Bio-Rad Laboratories Inc., Hercules, CA,
USA). The remaining heparinized blood was centri-
fuged at 880 g, 4°C for 10 min and plasma samples
were stored at −80°C until SELDI analysis. Bone mar-
row cells (BMCs) were estimated by flow cytometry
analysis. Cell-surface expression of CD34 in BMCs was
estimated using a FACS Calibur (Becton, Dickinson
and Company, Franklin Lakes, NJ, USA). BMCs were
depleted of erythrocytes by addition of lysing buffer
(BD Biosciences, San Jose, CA, USA) and then incu-
bated with anti-CD34 antibody (BD Biosciences) conju-
gated with fluorescein isothiocyanate (FITC) for
30 min on ice. After removal of free antibody, cells
were analyzed using a flow cytometer and Cell Quest
software (BD Biosciences). The fluorescence intensity
of cells gated in high forward and side scatter was
quantified. Data are expressed as a percentage of the
geometric means of the control mice given 0.5%
HPMC and DW.
All procedures were prospectively approved by the
Animal Care and Use Committee of Kyoto Prefectural
University of Medicine or by the Laboratory Animal
Committee of Tsumura & Co.Figure 1 Outline scheme of the treatment and sampling procedure. T
The timing of drug administration is indicated by arrows. Analysis of the blSELDI protein profiling
Each plasma sample was analyzed on two different array
surfaces: anion exchange (Q10) and cation exchange
(CM10). Sinapinic acid (SPA) was used as the energy
absorbing molecule (EAM). These materials were pur-
chased from Bio-Rad Laboratories Inc..
Plasma samples were thawed on ice and then mixed at
a ratio of 1:9 with urea denaturing buffer (7 M urea,
2 M thiourea, 1% dithiothreitol, 4% CHAPS and 2%
ampholyte) or phosphate-buffered saline (PBS) for
10 min on ice. Mixed samples were used for proteomic
profiling in duplicates. Binding of proteins and applying
of EAM to the array surfaces were performed in a 96-
well format bioprocessor using a Biomek2000 automatic
system (Beckman Coulter, Inc., Brea, CA, USA) [15,16].
The arrays were analyzed using a Protein Chip System
4000 Reader (PCS4000; Bio-Rad Laboratories, Inc.),
which was calibrated for mass accuracy using combined
‘all-in-one’ peptide standards (Bio-Rad Laboratories,
Inc.) and cytochrome c (Sigma-Aldrich, St. Louis, MO,
USA) for m/z 3000–10,000, and protein standard II
(Bio-Rad Laboratories, Inc.) for m/z 10,000-30,000. Data
were averaged from 795 laser shots for each spot. Spec-
tra collection and statistical analyses were performed
using the CiphergenExpress (version 3.0.6) software
package (Bio-Rad Laboratories, Inc.).
Purification and identification of biomarker candidates
Ion exchange fractionation was undertaken on a CM
Ceramic HyperD F Spin Column (Bio-Rad Laboratories,
Inc.) pre-equilibrated with binding/washing buffer
(100 mM sodium acetate, pH 4.0). Plasma samples were
diluted at a ratio of 1:1.5 in U9 buffer (9 M urea, 2%
CHAPS, 50 mM Tris–HCl, pH 9.0) and incubated for
30 min at 4°C on a rotator. Treated samples were then
diluted 1:9 in binding/washing buffer and applied to thehe drugs were orally administered to mice daily for 3, 5 and 7 days.
ood samples on days 3, 5 and 7 is indicated by asterisks.
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Samples applied to the column were first clarified by
centrifugation (80 g, 4°C for 3 min). The sample applied
spin column was centrifuged at 80 g at 4°C for 3 min.
The flow-through was collected as Fr.1-1. One hundred
and fifty microliters of binding/washing buffer was ap-
plied to the column and incubated for 5 min at 4°C on a
rotator. The washing step was repeated twice (collected
as Fr.1-2 and Fr.1-3). The bound proteins were eluted
using 150 μL of elution buffer (50 mM Tris–HCl, pH
8.0) 5 times (Fr.2-1, Fr.2-2, Fr.2-3, Fr.2-4 and Fr.2-5).
SELDI TOF-MS was used to monitor each fraction for
ions of interest.
Eluted fractions containing biomarker candidates were
pooled and concentrated by molecular weight cut-off
membrane fractionation (Amicon Ultra-0.5; Millipore
Corporation, Billerica, MA, USA). A biomarker candi-
date was identified using sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) coupled
with MS analysis. Concentrated fractions were separated
by SDS-PAGE using a precast 15% gel and Tris-Tricine
buffer. Bands were visualized by silver staining (EzStain
Silver; ATTO Corporation, Tokyo, Japan). Gel pieces
containing the proteins of interest were excised and sub-
jected to in-gel trypsin digestion, followed by liquid
chromatography–tandem mass spectrometry (LC–MS/
MS) analysis (performed by APRO Life Science Institute,
Inc., Tokushima, Japan). MS/MS spectra were submitted
to the database mining tool Mascot (Matrix Science,
London, UK) for identification.
Statistical analysis
For the in vivo study, statistical analysis was performed
using 1-way ANOVA. Student’s t-test was used toFigure 2 Comparison of white blood cell count. Comparison of white b
treated with 0.5% HPMC and DW; JTT, treated with 0.5% HPMC and 1 g/kg
with 10 mg/kg of TS-1 and 1 g/kg of JTT. Data represent means ± SE.determine the significance of differences between the
control and TS-1, and between TS-1 and TS-1 + JTT in
the dosed testing procedure [17]. In SELDI profiling
analysis, statistical analysis was performed using non
parametric Kruskal-Wallis H-test. Non-parametric
Mann–Whitney U-test was used to determine the sig-
nificance of differences between the control and TS-1,
and between TS-1 and TS-1 + JTT.
Results
Improvement in white blood cell count and bone marrow
suppression by JTT
Initially, we examined several dosages of TS-1 and
selected a dosage of 10 mg/kg because it induced evi-
dent myelosuppression without severe body weight
loss. JTT was used at a dosage of 1 g/kg, which has
been reported to be effective in various disease models
such as mitomycin C- and radiation-induced haemato-
poietic toxicity [18-20]. Thus, mice were orally given
10 mg/kg of TS-1 followed by 1 g/kg of JTT for 3, 5
and 7 days, and the WBC and BMC counts were
determined. The treatment and analysis schedule is
described in Figure 1.
After administration of TS-1, the WBC count was
decreased significantly on days 5 and 7, but it was
improved by coadministration of JTT on day 7
(Figure 2). Bone marrow suppression was evaluated by
geometric mean fluorescence intensity (GM) on the x
axis using a log scale. GM peaks were converted to a
linear scale to calculate the percentage of the daily
control (%DC). Administration of TS-1 led to a de-
crease in %DC at 3 days, but %DC was significantly
improved by coadministration of JTT at 5 and 7 days
(Figure 3).lood cell (WBC) count in treated mice on days 3, 5 and 7. Control,
of JTT; TS-1, treated with 10 mg/kg of TS-1 and DW; TS-1 + JTT, treated
Figure 3 Comparison of bone marrow cell by geometric mean fluorescence intensity. BMCs were labeled with anti-CD34 antibody
conjugated with FITC. Fluorescent intensities of labeled cells were gated in high forward. Geometric mean of fluorescent intesnsities were
calculated and represented as the ratio to the Control values. Data represent means ± SE.
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by SELDI protein profiling
Because chemotherapeutic drugs have a profound effect
on blood proteomics, a number of peaks are generally
changed with statistical significance in the protein pro-
file. Therefore, it is necessary to include additional cri-
teria for further investigation of possible biomarker
candidates. In the present study, because JTT treatment
clearly improved TS-1-induced myelosuppression, we
searched for peaks that were up- or down-regulated by
TS-1 treatment but whose changes were nullified by
coadministration of JTT. We compared SELDI profiles
among the control group, JTT group, TS-1 group, and
TS-1 + JTT group and found that peaks with m/z values
of 4135.5, 4223.1 and 4429.5 (Figure 4A) met the above
criterion. The intensity of all three peaks significantly
increased on day 3 after administration of TS-1 when
the decrease in WBC was still insignificant. In the TS-1
and JTT group, these peaks were not significantly chan-
ged as compared with the control group (Figure 4B, only
m/z 4223.1 shown). Intriguingly, on days 5 and 7 there
was no difference in the intensity of these three peaks
between the control and TS-1 groups (data not shown).
As a result, these peaks appeared to be changed prior to
a detectable decrease in WBC.
Identification of biomarker candidates by LC-MS/MS
The m/z 4223.1 peak gave the highest peak intensity
among the three biomarker candidates (Figure 4A), and
was therefore investigated further. First, in order to
characterize this candidate marker, fractions eluted from
the cation exchange spin column were applied to SELDIprotein chip arrays. The candidate marker, m/z 4223.1,
was detected in the following fractions; Fr.2-2, 2–3, 2–4
and 2–5 (Figure 5A). The fractions were concentrated
and 1.5 μg (Fr.2-2) and 20 μg (Fr.2-3, 2–4 and 2–5) of
protein were separated by SDS-PAGE (Figure 5B).
A relatively intense band with a molecular mass of ap-
proximately 6500 Da was present in Fr.2-3 but in none
of the other lanes. The band was extracted and analyzed
by SELDI TOF-MS. The band-extract produced a SELDI
peak identical to the protein with m/z 4223.1
(Figure 5C). The band was subjected to in-gel trypsin di-
gestion followed by LC-MS/MS.
The MS/MS spectra were submitted to Mascot
for identification. The mascot research results found
two high-scoring peptide sequences that matched the
C-terminal region of mouse albumin (Table 1A). Thus,
the candidate peptide is thought to be a C-terminal
fragment of mouse albumin, which contains an add-
itional CKDALA sequence that was not detected in the
LC-MS/MS analysis (Table 1B). The theoretical mass
value of the matched sequence (m/z 3644.1) was less
than the experimentally determined m/z value of 4223.1
using SELDI TOF-MS. However, inclusion of the
CKDALA sequence would give a theoretical m/z of
4245.8, which is almost identical to m/z 4223.1.
Discussion
5-Fluorouracil (5-FU) and its prodrug TF have been
demonstrated to possess potent anti-tumor activity
in vitro. However, their severe side effects, including
myelotoxicity, gastrointestinal toxicity (diarrhea and sto-
matitis) and central nervous system (CNS) disturbance,
Figure 4 Detection of biomarker candidates. A) Spectrum of the peaks of three biomarker candidates (arrows). The protein peaks were
detected on a CM10 chip. B) Representative SELDI analysis data of the m/z 4223.1 peak as a biomarker candidate. In each group, plots indicate
the intensity of the peak and bars represent the mean value.
Ogawa et al. BMC Complementary and Alternative Medicine 2012, 12:118 Page 6 of 10
http://www.biomedcentral.com/1472-6882/12/118mean that it is impossible for these drugs to achieve suf-
ficient clinical benefits. TS-1 was designed with the sim-
ultaneous aim of enhancing the efficacy of 5-FU while
reducing the associated adverse reaction. Specifically,
TS-1 includes both CDHP, an inhibitor of 5-FU degrad-
ation, to maintain an effective plasma concentration of
FT, and Oxo to reduce the level of gastrointestinal tox-
icity. By reducing gastrointestinal toxicity, which causes
great discomfort to patients, it is possible to use TS-1
for an extended period of time. Thus, TS-1 has become
the most frequently-used anti-cancer drug for the treat-
ment of cancer patients in Japan [3].
TS-1 is administered orally for 4 weeks, followed by a
2-week rest. This treatment protocol can be repeated if
no serious side effects are apparent. Nonetheless, TS-1
has been reported to cause a variety of adverse reactions,
such as anemia, leukopenia, neutropenia, diarrhea,
thrombocytopenia, stomatitis, anorexia and proteinuria
[21]. In particular, TS-1 suppression of bone marrow is a
very serious problem. When a decrease in WBC count is
detected in TS-1-treated patients, TS-1 therapy must be
immediately discontinued. If the development of TS-1-
induced leukopenia can be inhibited, however, the
patients can continue to receive therapy. Additionally,the dosage of anticancer agent might even be increased
to improve therapeutic gain. This would be a great bene-
fit to patients with gastroenterological cancer.
Our study aimed to solve this problem through three
individual steps. First, we investigated whether JTT has a
preventive effect on bone marrow suppression induced
by TS-1. Second, we attempted to identify candidate bio-
markers that can detect myelosuppression before the
onset of leukopenia. If we use appropriate precautionary
measures such as the strict control of the treatment
protocol of TS-1 and/or the prophylactic administration
of hematopoietic reagents (e.g. G-CSF), the discontinu-
ation of TS-1 therapy may be avoided or at least delayed.
Third, we investigated whether the candidate biomarker
could predict whether the patient is a “JTT-responder”.
JTT has been reported to improve the general condi-
tion of cancer patients receiving chemotherapy and/or
radiation therapy [22]. In mice, it has been suggested
that JTT improves the decline in bone marrow function
induced by anticancer therapy or radiotherapy and that
the effect is mediated, at least partly, by enhancing the
proliferation of hematopoietic stem cells. This effect has
been demonstrated as an increase in colony-forming
units in spleen (CFU-S) and/or granulocyte-macrophage
Figure 5 Purification of a biomarker candidate. Purification of the biomarker candidate peak at m/z 4223.1 involved using a combination of
spin column and SDS-PAGE. A) Spectra of peak fractions eluted from the cation exchange spin column; before fractionation plasma, Fr. 2–2, Fr. 2–3,
Fr. 2–4 and Fr. 2–5. The peaks were detected on a CM10 chip. The candidate peak is marked by an arrow. B) Each fraction was separated
by SDS-PAGE and protein bands were visualized by silver staining. C) The band marked by an arrow in the Fr.2-3 lane was extracted from
the gel and then analyzed by SELDI TOF-MS.
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C-treated or irradiated animals [18,20], and is mediated by
mitogenic activity of oleic acid and linolenic acid con-
tained in JTT. The same mechanism may be involved in
the inhibition of TS-1-induced leukopenia/bone marrow
suppression demonstrated in the present study; however,
further extensive studies are necessary to clarify this point.
It has been long supposed that there are distinct
groups of responders and non-responders to each
Kampo medicine. Certain Kampo medicines have been
reported to produce a dramatic therapeutic effect in “re-
sponder” patients, but there are always a number of
“non-responder” patients. Many clinical trials usingTable 1 Peptide sequences of m/z 4223.1 determined from th






B 551 TALAELVKHK PKATAEQLKT VMDDFAQFLD TCCKAADKD
601 TRCKDALA
A) Peptide sequences determined from LC-MS/MS analysis. B) Amino acid sequence
Prot entry P07724). Matched peptides shown in Bold.Kampo medicines, including more than 10 multicenter,
placebo-controlled, double-blind studies, have demon-
strated significant beneficial effects of Kampo medicines
[23,24]. However, these trials also suggest that it is im-
portant to distinguish responders from non-responders
at an early stage of therapy to achieve the anticipated
therapeutic outcome. Thus, in order to maximize the
beneficial effects of Kampo medicines in modern med-
ical practice it is crucially important to identify a suitable
biomarker to distinguish a “responder” from a “non-
responder”.
Although a huge number of research papers have been
devoted to identifying biomarkers, few biomarker(s) havee LC-MS/MS analysis
Residues Sequence
570-584 K.TVMDDFAQFLDTCCK.A
570-584 K.TVMDDFAQFLDTCCK.A Oxidation (M)
585-602 K.AADKDTCFSTEGPNLVTR.C
585-602 K.AADKDTCFSTEGPNLVTR.C Propionamide (C)
589-602 K.DTCFSTEGPNLVTR.C
T CFSTEGPNLV
of the C-terminal peptide (from residue 551 to 608) of mouse albumin (Swiss-
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omic technology is one of the most effective methods
for identifying biomarkers. SELDI is an MS-based prote-
omic technique that has been used in the discovery of
disease-related biomarkers derived from biological fluids.
We have previously reported several biomarker candi-
dates for Kampo medicines using SELDI [15,16,25].
Among them, haptoglobin alpha 1 chain may be used to
predict the efficacy of the Kampo medicine keishibukur-
yogan in the treatment of rheumatoid arthritis. The
strategy used in the present study employed SELDI to
find a predictive marker for TS-1-induced leukopenia.
Specifically, we focused on protein peaks whose intensity
changed significantly prior to a decrease in WBC count.
To generate a shortlist of candidate proteins, we focused
on peaks that changed upon treatment with TS-1 but
were normalized by co-treatment with JTT. Using this
approach, we identified three biomarker candidates,
which all increased 3 days after administration of TS-1
although coadministration of JTT reduced these
changes. Interestingly, the TS-1-induced up-regulation
of these biomarker candidates was only transient, be-
cause they showed no significant difference on days 5
and 7 as compared with the negative control. Our
results suggest that these candidates may be induced in
the early phase of TS-1-mediated myelosuppression. As
such, these candidate biomarkers may play an important
role in the development of a serious adverse effect of
TS-1.
We successfully identified one (m/z 4223.1) of the
three candidate biomarkers as the C-terminal fragment
of albumin using a combination of SDS-PAGE and LC-
MS/MS analysis. It is implausible that this albumin frag-
ment directly mediates the side effects associated with
administration of TS-1, such as leukocytopenia and bone
marrow suppression. Therefore, we believe that the albu-
min fragment may be derived from early molecular
events during the onset of bone marrow suppression. In-
deed, a decrease in albumin is associated with myelosup-
pression induced by several chemotherapeutic reagents,
including TS-1 [26-30]. Recent studies have suggested
that the plasminogen fibrinolytic pathway is required for
hematopoietic regeneration [31,32]. Thus, dynamic alter-
ation of the protease-protease inhibitor network might
occur in myelosuppression. We intend to investigate
whether JTT directly inhibits the protease responsible
for producing the albumin fragment of m/z 4223.1 in a
future study.
Albumin fragments of various length and amino acid
sequence have been identified as biomarker candidates
for other diseases [33-35]. Those results suggest that the
fragments are generated from circulating albumin by
specific or nonspecific proteases activated in various dis-
ease states. Albumin is the most abundant protein inblood and has a diverse range of functions, including
maintenance of intravascular volume and colloid os-
motic pressure, binding and transport of various mole-
cules (including hormones, lipid and drugs), antioxidant
and anti-inflammatory actions, and exertion of a stabiliz-
ing effect on the endothelium [36-39]. Thus, albumin
may act as a “buffer” against stress from disease and/or
exposure to certain drugs. Various mediators (e.g., in-
flammatory, oxidative, fibrolytic, chemotactic), including
proteases liberated from injured or disabled organs,
might be “buffered” or “neutralized” by inactivation upon
binding to, reduction with, and digestion of, circulating
albumin. It must be noted that fragments of various
major serum proteins, such as haptoglobins [15], trans-
ferrin [40], fibronectin and apolipoproteins [41], have
also been identified as serum biomarkers in various dis-
eases. Abundant serum proteins might represent a reser-
voir of “scapegoats” for activated proteases. Identification
of the protease responsible for generation of the present
peptide will contribute to elucidating the mechanisms
underlying both the development of bone marrow sup-
pression by TS-1 and the improvement by JTT.
It should be noted, however, that there are species dif-
ferences in the amino acid sequence between human
and murine albumin. The peptide fragment found in this
study is supposed to be generated from the cleavage of
mouse albumin at lysine 569, which corresponds to ly-
sine 569 of human albumin. The overall identity and
similarity of the amino acid sequence of mouse and
human albumin (consisting of 609 and 608 AA, respect-
ively) are high (72.3 and 92.9%, respectively), and those
of the sequence of the anterior segment of the cleavage
sites (541–569) are also high (86.2 and 93.1%, respect-
ively). It therefore is possible that a similar fragment may
be generated in human. On the other hand, the identity
and similarity of the posterior sequence (570–609) are
lower (55 and 82.5%, respectively). Furthermore, recogni-
tion of the cleavage site by proteases has varying degrees
of stringency depending on each protease. Therefore val-
idation studies in human patients, as well as clarification
of the protease responsible for generation of the frag-
ment, are necessary. We plan to execute these studies in
the near future in our laboratory.
Conclusions
Our results suggest that bone marrow suppression
induced by administration of TS-1 in mice may be
improved by coadministration of JTT. We used SELDI
technology combined with SDS-PAGE and LC-MS/MS
analysis to identify a specific albumin C-terminal frag-
ment from plasma that transiently increases in mice
treated with TS-1. Moreover, this fragment was
decreased in the plasma of mice co-treated with JTT.
The albumin fragment may be a suitable biomarker for
Ogawa et al. BMC Complementary and Alternative Medicine 2012, 12:118 Page 9 of 10
http://www.biomedcentral.com/1472-6882/12/118predicting the onset of TS-1-induced myelosuppression.
However, the sensitivity and specificity of the biomarker
candidate must be validated in future clinical studies.
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